Marksans Pharma Limited
MARKSANS
Rank in Stocks
#7028
Marksans Pharma Limited, along with its subsidiaries, operates internationally,... Marksans Pharma Limited, along with its subsidiaries, operates internationally, engaging in the full spectrum of generic pharmaceutical formulation activities, from research and development and manufacturing to marketing, distribution, and sales. The company's extensive product portfolio addresses a wide array of medical needs across numerous therapeutic categories. These include pain management (analgesics), conditions such as benign prostatic hyperplasia and various forms of diabetes, neurological disorders like epilepsy, anti-inflammatory conditions, hyperparathyroidism, and gastrointestinal issues like those requiring antacids or treatments for gastroenterology. Marksans Pharma also develops solutions for cardiovascular health, hormonal imbalances, oncology, gynecology, and hypertension, alongside producing antibiotics, antifungals, antiulceratives, vitamins, dermatological preparations, cephalosporins, injectables, anti-allergy, and antibacterial medications. Furthermore, the firm offers contract research and manufacturing services. Established in 1992, its corporate headquarters are situated in Mumbai, India.
Share Price
$3.29
Last synced: 2026-11-09
Market Cap
$1.49B
Change (1 day)
2.22%
Change (1 year)
49.92%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Marksans Pharma Limited (MARKSANS)
Category
Healthcare
EPS for Marksans Pharma Limited (MARKSANS)
EPS as of September 2026 TTM: $0.13
According to Marksans Pharma Limited's latest financial reports, its current EPS (TTM) is $0.13. At the end of 2025 the company had an EPS of $0.10, an increase over its 2024 EPS of $0.08.
EPS history for Marksans Pharma Limited from 2005 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.13 | 29.80% |
| 2025 | $0.10 | 18.31% |
| 2024 | $0.08 | 6.41% |
| 2023 | $0.08 | 31.31% |
| 2022 | $0.06 | -25.38% |
| 2021 | $0.08 | 109.47% |
| 2020 | $0.04 | 33.80% |
| 2019 | $0.03 | 130.89% |
| 2018 | $0.01 | 261.76% |
| 2017 | 0.00 | -88.28% |
| 2016 | $0.03 | -32.24% |
| 2015 | $0.04 | 37.18% |
| 2014 | $0.03 | 42.47% |
| 2013 | $0.02 | -122.86% |
| 2012 | $-0.10 | -29.66% |
| 2011 | $-0.14 | 2,170.00% |
| 2010 | $-0.01 | 33.33% |
| 2009 | 0.00 | -142.06% |
| 2008 | $0.01 | 143.18% |
| 2007 | 0.00 | -69.44% |
| 2006 | $0.01 | 25.22% |
| 2005 | $0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $30.89 | 23,698.15% |
US
|
|
| $6.60 | 4,984.75% |
US
|
|
| $5.83 | 4,391.53% |
US
|
|
| $0.98 | 655.01% |
US
|
|
| $18.54 | 14,185.05% |
CH
|
Questions about Marksans Pharma Limited's earnings per share (EPS)
What is Marksans Pharma Limited's earnings per share (EPS)?
Marksans Pharma Limited's earnings per share (EPS) over the last twelve months is $0.13, as of Sep 2026.
What was Marksans Pharma Limited's earnings per share (EPS) in 2025?
In 2025, Marksans Pharma Limited's earnings per share (EPS) was $0.10, 25.00% more than in 2024 ($0.08).
How has Marksans Pharma Limited's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Marksans Pharma Limited's earnings per share (EPS) went from $0.04 to $0.10, an average growth of 20.11% a year.
How does Marksans Pharma Limited's earnings per share (EPS) compare with similar companies?
Marksans Pharma Limited's earnings per share (EPS) ($0.13) is lower than that of all 5 similar companies listed above. The highest among them is Eli Lilly and Company, with $30.89.